Lilly Bets Up to $2.25 Billion on Profluent's AI-Designed Recombinases, Pushing Gene Editing Beyond CRISPR Into Kilobase-Scale Territory
Eli Lilly's deal with Bezos-backed Profluent funds AI-designed recombinases that aim to insert entire genes, going beyond CRISPR's localized cuts.
4 min read3 sources